Aficamten Drug Asset Due Diligence Report 2026

This Aficamten Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Aficamten can convert its Small molecule drug profile and Cardiac myosin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Aficamten (query alias: aficamten)
Modality / target	Small molecule drug; Cardiac myosin; Cardiac myosin inhibitors
Highest global status	Approved
Originator	Cytokinetics, Inc.
Active developers	Cytokinetics, Inc., Bayer AG

The MCP disease footprint includes Hypertrophic obstructive cardiomyopathy, Hypertrophic Cardiomyopathy without Obstruction, Cardiomyopathy, Hypertrophic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07600177	Phase 4	Recruiting	40	Safety Endpoints
NCT07023341	Phase 3	Active, not recruiting	36	Change in Valsava LVOT-G
JPRN-jRCT2031250066	Phase 3	Recruiting	30	Dual primary endpoints of: - Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) [Time Frame: Baseline to Week 36] - Change in pVO2 from baseline to Week 36"

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 3; n=175; evaluation: not stated. Reported fields: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean) = -1.24 mL/kg/min (Standard Deviation, 2.186); Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean) = 1.07 mL/kg/min (Standard Deviation, 2.767); Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean): Least Squares Mean Difference = 2.30(95% CI, 1.52 - 3.07), P-Value = <0.0001

A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Phase 3; n=282; evaluation: not stated. Reported fields: Change From Baseline in pVO2 at Week 24(Least Squares Mean) = 0.02 mL/kg/min (Standard Error, 0.25); Change From Baseline in pVO2 at Week 24(Least Squares Mean): Mean Difference (Final Values) = 1.74(95% CI, 1.04 - 2.44), P-Value = <0.0001; Change From Baseline in pVO2 at Week 24(Least Squares Mean) = 1.76 mL/kg/min (Standard Error, 0.25)

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy

Phase 2; n=96; evaluation: not stated. Reported fields: -; Incidence of Adverse Events (AEs) = 11 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Aficamten addresses Hypertrophic obstructive cardiomyopathy, Hypertrophic Cardiomyopathy without Obstruction, Cardiomyopathy, Hypertrophic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-12-20	CORXEL and Sanofi Announce an Agreement for Aficamten in Greater China Markets	NDA/BLA	Financial terms not disclosed
2024-11-19	Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan	NDA/BLA	US$52.9M upfront; US$580.0M milestones
2022-01-07	Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline	Phase 2	US$50.0M upfront; US$1,025.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Co-crystals and its solid-state forms of aficamten”. The milestone feed surfaced a patent-application signal described as “New process for preparation of aficamten”. The milestone feed surfaced a patent-application signal described as “Solid state forms of aficamten and process for preparation thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO